An interventional study of Routine Standard Care and Telepharmacy Intervention in Anemia and Hemodialysis, sponsored by Damanhour University. Completed at 2 sites in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Damanhour University · Not applicable, Interventional, and Supportive care
This study looked at whether regular follow-up by pharmacists through phone calls (telepharmacy) can help improve the treatment of anaemia in patients undergoing haemodialysis.
Anaemia is very common in patients with kidney disease and can cause fatigue, weakness, and an increased risk of heart problems. It is usually treated with medications such as erythropoietin (EPO), but managing the correct dose and ensuring patients follow treatment can be challenging. In this study, patients were divided into two groups. One group received standard care, while the other group received additional support from pharmacists through regular phone calls. During these calls, pharmacists helped patients understand their medications, encouraged adherence, monitored symptoms, and worked with doctors to adjust treatment when needed.
1,768 studies on the registry are indexed under Anemia; 244 are open to participants now.
This study's enrollment of 101 is close to the median of 96 across 1,318 interventional studies indexed under Anemia.
Browse Anemia studies →Damanhour University is the lead sponsor of 78 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants assigned to this arm received routine hemodialysis care according to standard clinical practice without additional telepharmacy support. This included regular physician follow-up, laboratory monitoring, and medication management as determined by the treating healthcare team. No structured pharmacist-led remote monitoring or scheduled telecommunication-based interventions were provided.
Other: Routine Standard Care
Participants assigned to this arm received routine maintenance hemodialysis care in addition to a structured telepharmacy intervention delivered by trained clinical pharmacists over a 5-month period. The intervention included scheduled telephone follow-up, medication review, adherence assessment, individualized counseling, monitoring of laboratory results, identification and resolution of drug-related problems, and collaboration with treating physicians to optimize erythropoiesis-stimulating agent (ESA) therapy and overall medication management.
Other: Routine Standard Care · Behavioral: Telepharmacy Intervention
Participants assigned to the Routine Standard Care intervention received routine maintenance hemodialysis care according to the participating hospitals' standard clinical practice. Standard care included regular nephrologist follow-up, routine laboratory monitoring (including hemoglobin and other relevant biochemical parameters), prescription and adjustment of erythropoiesis-stimulating agents (ESAs) and other medications as clinically indicated, and conventional nursing and dialysis care. Medication management and treatment decisions were made during routine clinical visits. Unlike the experimental arm, participants did not receive the structured telepharmacy intervention, including scheduled telephone consultations, proactive medication review, adherence counseling, pharmacist-initiated remote monitoring, or pharmacist-led therapeutic follow-up.
Pharmacist-led remote care including scheduled telephone follow-up, medication review, adherence assessment, individualized counseling, monitoring of laboratory results, identification and resolution of drug-related problems, and collaboration with physicians to optimize erythropoiesis-stimulating agent (ESA) therapy and overall medication management. Participants continued to receive routine standard care throughout the study in addition to the telepharmacy intervention.
Change in hemoglobin (Hb) level
Time frame: 5 months
Change in erythropoietin dose
Time frame: 5 months
Number of identified drug-related problems
Time frame: 5 months
Plan to share: No
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Damanhour University